Author: perbinder
Research highlights: An artificial intelligence-enabled digital stethoscope could be an easy and effective way to diagnose cardiac dysfunction during and immediately after pregnancy. The stethoscope records electrocardiograms and heart sounds and uses an AI algorithm to predict possible heart muscle weakness. AI-guided screening using a digital stethoscope identified twice as many cases of pregnancy-related cardiomyopathy among Nigerian women compared to standard clinical care. Embargoed until Monday, November 13, 2023 at 9:45 a.m. ET PHILADELPHIA, November 13, 2023 — Electrocardiogram (EKG)-based screening using an artificial intelligence-enabled digital stethoscope can detect peripartum cardiomyopathy, a disease of the heart muscle in pregnant…
Share on PinterestThe GLP-1 drug semaglutide is being studied as a way to help fight heart disease.Antonio Diaz/Getty ImagesNew research presented at the American Heart Association Scientific Sessions shows that semaglutide, the active ingredient in Ozempic and Wigovy, has a significant impact on heart health.Evidence shows that patients treated with GLP-1 drugs have a reduced risk of heart attack and stroke.Symptoms of heart failure also improved when treated with semaglutide.Semaglutide is a GLP-1 drug originally prescribed for diabetes and then obesity, and may soon treat cardiovascular disease as well.Over the weekend, 2023 American Heart Association Scientific Sessionsresearchers published compelling evidence…
Pivotal new research suggests that the weight loss drug WeGoBe reduces the risk of heart attack, stroke, and death from cardiovascular disease by 20 percent in overweight or obese heart patients, suggesting that these patients’ This is a significant effect that has the potential to change standard treatment.”We have just identified new best practices,” said Dr. Clyde Yancey, chief of cardiology at Northwestern Medical School. He was not involved in this study. However, this study also shows what effects this drug has on the heart, whether through weight loss itself or other mechanisms, and whether this drug is comparable in…
share Results from a multicenter, international clinical trial reported by Cleveland Clinic physicians showed that semaglutide reduced cardiovascular events by 20% in adults who were overweight or obese, had cardiovascular disease, and did not have diabetes. It shows. Semaglutide is primarily prescribed to adults with type 2 diabetes, but it is also approved for chronic weight management in adults who are obese or overweight and have at least one other health problem. In this trial, patients treated with semaglutide lost an average of 9.4% in body weight and saw improvements in other risk factors for cardiovascular disease. result obtained from…
File photo: A 0.25 mg injection pen for Novo Nordisk’s weight loss drug Wigoby is shown in this photo illustration on September 1, 2023 in Oslo, Norway. Photo credit: Victoria Klesty/REUTERS Popular weight loss drug Wegoby reduced the risk of serious heart disease by 20 percent in a large international study, and experts say it could change the way doctors treat certain heart disease patients. There is. This study documents for the first time that obesity drugs can not only help people lose weight but also safely prevent heart attack, stroke, or heart-related death in people who already have heart…
High cholesterol, high blood pressure, diabetes, and smoking are well-known risks for heart disease, but not everyone who has a heart attack has these risks. In fact, previous studies have shown that 14% to 27% of heart attack patients have none of these risk factors.Now, a new study by researchers at Intermountain Health in Salt Lake City has found that these patients had something in common. All of them tended to have high coronary artery calcium levels. Results of a new Intermountain study detect this type of plaque buildup even in the absence of four standard modifiable risk factors so…
Still life of Wegovy, an injectable prescription weight loss drug that has helped obese people. It should be used in conjunction with a weight loss plan and physical activity. Michael Silk | UCG | Getty ImagesNovo Nordisk’s Wegoby has demonstrated in a carefully monitored trial that it reduced the risk of serious cardiovascular complications in people with obesity and heart disease, and was particularly effective against heart attacks . This is a promising new frontier for this drug.The Select study, which included approximately 17,500 people, tested Wegovy on people with obesity and heart disease, but not diabetes. Detailed results from…
Research highlights: A multinational study compared test results of heart attack patients with anemia who received blood transfusions when their hemoglobin concentration levels were 8 g/dL or 10 g/dL. Although the results did not reach statistical significance, they showed that blood transfusions to keep hemoglobin levels above 10 g/dL for anemic patients hospitalized with heart attacks may improve their health. As the largest study to evaluate blood transfusion thresholds in people after a heart attack, the results could help guide clinicians’ decision-making when treating heart attack patients with anemia. Embargoed until Saturday, November 11, 2023 at 10:10 a.m. ET…
Research highlights: A large international clinical trial found that people who were obese or overweight but did not have diabetes had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease when they took semaglutide for more than three years; 9.4% of the body decreased. weight. Semaglutide is her GLP-1 drug that is primarily prescribed to her type 2 diabetic patients. It is also approved by the FDA for weight loss in obese individuals. This double-blind, randomized trial included 41 patients who were overweight or obese, had a previous heart attack, stroke, or peripheral artery disease,…
Highlights of the statement: New American Heart Association PreventsTM The risk calculator estimates the 10-year and 30-year total cardiovascular disease risk for people age 30 and older. This calculator estimates your risk of heart attack, stroke, and for the first time heart failure. This equation is gender-neutral and race-neutral, acknowledging that race can include indicators of social determinants of health rather than biological factors. It is the first risk calculator to combine cardiovascular, renal, and metabolic health measurements to estimate cardiovascular disease risk. This calculator was developed using health information from more than 6 million adults, including people from…